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A few days ago (Nov 18, 2013) the results of the large 
prospective 
 were presented and pub-
lished. CORAL enrolled 947 participants who had athero-
sclerotic renal artery stenosis (ARAS),  60% and either 
uncontrolled systolic hypertension despite treatment with  2 
anti-hypertensive drugs or stage 3 chronic kidney disease 
(CKD) [1]. CORAL randomly assigned patients to medical 
therapy plus renal-artery stenting or medical therapy alone. 
The median follow-up period was 43 months and the pri-
mary endpoint was a composite of death from cardiovascular 
disease (CVD) or renal causes, myocardial infarction (MI), 
stroke, congestive heart failure, progression of renal insuffi-
ciency, or need for renal replacement therapy. Results 
showed that the addition of renal-artery stenting to thorough 
multifactorial medical therapy did not contribute a signifi-
cant clinical benefit with respect to the prevention of CVD 
events or renal function deterioration. Adverse CVD or renal 
events occurred in 35.1% of patients who received stenting 
and 35.8% of those on medical therapy alone (p=0.58) [1]. 
Thus, the authors concluded that renal artery stenting was 
not superior to optimal medical therapy alone for moderately 
severe ARAS [1]. 
The results of CORAL have a direct impact on clinical 
practice questioning the need for renal artery stenting in pa-
tients managed with optimal medical therapy. The message 
seems to be very simple. If patients have ARAS and high 
blood pressure, they need a very aggressive comprehensive 
medical therapy before considering any interventional pro-
cedure. 
A recent meta-analysis investigated CVD outcome in pa-
tients with ARAS treated either with renal angioplasty or 
antihypertensive drug therapy [2]. Pooled data from 5 studies 
(n=1,159 patients) showed that during the 2-year follow-up 
there were no significant clinical outcome differences be-
tween angioplasty and medical therapy [2], both in patients  
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with or without CKD. In another study [3] it was shown that 
patients with ARAS and normal or near normal renal func-
tion (creatinine 2.0 mg/dl) can be safely treated with effec-
tive drug treatment, with a small decrease in GFR. For pa-
tients who have atherosclerotic MI, stroke or renal impair-
ment, renal artery stenting may further reduce blood pressure 
and delay the deterioration or even improve renal function 
[3]. 
The Angioplasty and Stenting for Renal Artery Lesions 
(ASTRAL) trial (n =867) [4], although criticised by some for 
methodological issues [5], results showed that there were no 
meaningful clinical benefit from revascularization in patients 
with ARAS; however considerable risks were present [4].  
On the other hand, in patients with renovascular hyper-
tension due to fibromuscular dysplasia (RAFMD) and/or the 
combination of RAFMD with ARAS, angioplasty is the 
method of choice and has favourable short- and long-term 
CVD and renal clinical outcomes [6]. 
The take away message from all the above is that prior 
trials showed similar results in mild ARAS; this study estab-
lished the futility of stenting for a higher severity (moderate 
severity) of the disease. Substantially severe forms of ARAS 
will probably have to undergo renal angioplasty with stent-
ing, especially when flash pulmonary oedema occurs [7-9]. 
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